MRS Measurement of Glutamate and GABA Metabolism in Brain

NCT00109174 | Recruiting FDA Device

• 2 other identifiers: 05014405-M-0144
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

This study will use magnetic resonance spectroscopy (MRS) to measure in the brain the transfer of \[13\]C as it is naturally metabolized from glucose to specific chemical transmitters. From this method, we can measure the rate of production of an important excitatory neurotransmitter (glutamate) as well as an inhibitory neurotransmitter (GABA).

Conditions

Normal Physiology

Keywords

Glutamate; Excitatory Amino Acid; Neurochemistry; Brain; Magnetic Resonance Spectroscopy

Outcome Measures

Primary Outcomes (1)

• The primary outcome is the quality of the MR spectroscopy which includes spectrum signal-to-noise (SNR)\ ratio, spectral lineshape, linewidth, and resolution.

  To obtain more accurate and reliable MRS data from the human brain

  prospective and ongoing

Secondary Outcomes (1)

• The secondary outcome is the performance improvements of the scanner hardware, software and methodology

  prospective and ongoing

Study Arms (1)

One arm

OTHER

Subjects receive the same test

Device: 3T and 7T device

Interventions

3T and 7T device DEVICE

3T and 7T device

One arm

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age
• Able to give written informed consent
• Healthy based on medical history and physical exam
• Enrolled in Protocol 01-M-0254 or Protocol 17-M-0181

You may not qualify if:

• Any current Axis 1 diagnosis
• Clinically significant laboratory abnormalities
• Positive HIV test
• Metallic foreign bodies that would be affected by the magnetic resonance imaging (MRI) magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
• History of neurological illness or injury with the potential to affect study data interpretation, such as multiple sclerosis, Parkinson s disease, seizure disorder or traumatic brain injury
• Prescription psychotropic medication; drug free less than 8 weeks (anticholinergics, benzodiazepine, fluoxetine, antipsychotics, and anticonvulsants)
• Serious medical illness as determined from H\&P or laboratory testing including Diabetes
• Inability to lie flat on camera bed for about two and a half hours
• Pregnant or breastfeeding
• Current substance use disorder based on DSM-5
• NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy.

Sponsors & Collaborators

• National Institute of Mental Health (NIMH): lead

Study Sites (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

RECRUITING

Related Links

• NIH Clinical Center Detailed Web Page

Study Officials

• Li An, Ph.D.

  National Institute of Mental Health (NIMH)

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Christopher S Johnson

CONTACT

(301) 402-6695; johnsonchri@mail.nih.gov

Li An, Ph.D.

CONTACT

(301) 896-2882; anl@mail.nih.gov

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 22, 2005
• First Posted: April 25, 2005
• Study Start: September 6, 2006
• Primary Completion (Estimated): January 11, 2030
• Study Completion (Estimated): March 11, 2030
• Last Updated: April 20, 2026

Record last verified: 2025-08-08

Locations

US (1)